Collaboration will investigate next-generation cancer therapies 

PhoreMost, a UK-based biopharmaceutical company developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, have collaborated to study oncology targets currently considered undruggable.  

The agreement 

The POLARISqb Tachyon quantum computing platform will be used to scan billions of molecules from a large chemical space, to find novel molecular drugs, based on the information obtained from PhoreMost’s SITESEEKER phenotypic screening platform. This partnership aims to discover and develop the next generation of oncology therapies. 

Official comments 

Dr Shahar Keinan, POLARISqb’s CEO, said: “Quantum Computing technology is coming of age, allowing us to revolutionise drug discovery timelines and budgets, while improving the overall profile of the designed drugs. The experience and speed of PhoreMost’s technology is a great match to POLARISqb and we are excited to work together.”  

Dr Chris Torrance, CEO, PhoreMost, commented: “This partnership represents the ultimate ambition for any collaboration between biology and technology, where the full diversity of newly identified druggable disease targets generated by biological PROTEINi shape-libraries can now be married to the most logical and rapid method of finding small-molecule drugs to them. This best-in-class intersection of biotech and AI is going to be an exciting and transformative milestone for the entire pharmaceutical industry.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free